These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31132584)

  • 1. Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study).
    Pina LM; Dong X; Zhang L; Samtani MN; Michelson AD; Justino H; Bonnet D; Harris KC; Jefferies J; McCrindle BW; Li JS
    Am Heart J; 2019 Jul; 213():97-104. PubMed ID: 31132584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study.
    Zhu P; Willmann S; Zhou W; Yang H; Michelson AD; McCrindle BW; Li JS; Harris KC; Pina LM; Weber T; Nessel K; Lesko LJ; Kubitza D; Zannikos P
    J Clin Pharmacol; 2022 Feb; 62(2):220-231. PubMed ID: 34524700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study.
    McCrindle BW; Michelson AD; Van Bergen AH; Suzana Horowitz E; Pablo Sandoval J; Justino H; Harris KC; Jefferies JL; Miriam Pina L; Peluso C; Nessel K; Lu W; Li JS;
    J Am Heart Assoc; 2021 Nov; 10(22):e021765. PubMed ID: 34558312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children.
    Monagle P; Cochrane A; Roberts R; Manlhiot C; Weintraub R; Szechtman B; Hughes M; Andrew M; McCrindle BW;
    J Am Coll Cardiol; 2011 Aug; 58(6):645-51. PubMed ID: 21798429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure.
    McCrindle BW; Manlhiot C; Cochrane A; Roberts R; Hughes M; Szechtman B; Weintraub R; Andrew M; Monagle P;
    J Am Coll Cardiol; 2013 Jan; 61(3):346-53. PubMed ID: 23246393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictions.
    Willmann S; Coboeken K; Zhang Y; Mayer H; Ince I; Mesic E; Thelen K; Kubitza D; Lensing AWA; Yang H; Zhu P; Mück W; Drenth HJ; Lippert J
    CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1195-1207. PubMed ID: 34292671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of warfarin versus aspirin after Fontan surgery.
    Attard C; Monagle PT; d'Udekem Y; Mackay MT; Briody J; Cordina R; Hassan EB; Simm P; Rice K; Ignjatovic V;
    J Thorac Cardiovasc Surg; 2021 Oct; 162(4):1218-1228.e3. PubMed ID: 33563422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology of thrombosis and anticoagulation post Fontan surgery.
    Attard C; Huang J; Monagle P; Ignjatovic V
    Thromb Res; 2018 Dec; 172():204-213. PubMed ID: 29685556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influences of Obesity and Bariatric Surgery on the Clinical and Pharmacologic Profile of Rivaroxaban.
    Moore KT; Kröll D
    Am J Med; 2017 Sep; 130(9):1024-1032. PubMed ID: 28601546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban, an oral direct factor Xa inhibitor.
    Piccini JP; Patel MR; Mahaffey KW; Fox KA; Califf RM
    Expert Opin Investig Drugs; 2008 Jun; 17(6):925-37. PubMed ID: 18491993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
    Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
    Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery.
    Sychev D; Minnigulov R; Bochkov P; Ryzhikova K; Yudina I; Lychagin A; Morozova T
    High Blood Press Cardiovasc Prev; 2019 Oct; 26(5):413-420. PubMed ID: 31617197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    Windecker S; Tijssen J; Giustino G; Guimarães AH; Mehran R; Valgimigli M; Vranckx P; Welsh RC; Baber U; van Es GA; Wildgoose P; Volkl AA; Zazula A; Thomitzek K; Hemmrich M; Dangas GD
    Am Heart J; 2017 Feb; 184():81-87. PubMed ID: 27892890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both.
    Fox KAA; Anand SS; Aboyans V; Cowie MR; Debus ES; Zeymer U; Monje D; Vogtländer K; Lawatscheck R; Gay A
    Am Heart J; 2020 Apr; 222():166-173. PubMed ID: 32092505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis.
    Dias C; Moore KT; Murphy J; Ariyawansa J; Smith W; Mills RM; Weir MR
    Am J Nephrol; 2016; 43(4):229-36. PubMed ID: 27100875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombotic complications and thromboprophylaxis across all three stages of single ventricle heart palliation.
    Manlhiot C; Brandão LR; Kwok J; Kegel S; Menjak IB; Carew CL; Chan AK; Schwartz SM; Sivarajan VB; Caldarone CA; Van Arsdell GS; McCrindle BW
    J Pediatr; 2012 Sep; 161(3):513-519.e3. PubMed ID: 22513267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study.
    Yasuda S; Kaikita K; Ogawa H; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K
    Int J Cardiol; 2018 Aug; 265():108-112. PubMed ID: 29764706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
    JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.
    Leef GC; Hellkamp AS; Patel MR; Becker RC; Berkowitz SD; Breithardt G; Halperin JL; Hankey GJ; Hacke W; Nessel CC; Singer DE; Fox KAA; Mahaffey KW; Piccini JP
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28615214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban versus high dose nadroparin for thromboprophylaxis after hip or knee arthroplasty.
    Heckmann M; Thermann H; Heckmann F
    Hamostaseologie; 2015; 35(4):358-63. PubMed ID: 26194889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.